S&P ASX All Technology

3,433.00

1.97%

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

IMMP

Immutep (IMMP)

Immutep Ltd

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IMMP

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
24/09/2024	22:00	GlobeNewswire Inc.	Immutep Receives A$3.6 million R&D Tax Incentive from French Government	NASDAQ:IMMP	Immutep Ltd
24/09/2024	20:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMMP	Immutep Ltd
18/09/2024	22:00	GlobeNewswire Inc.	New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma	NASDAQ:IMMP	Immutep Ltd
16/09/2024	22:00	GlobeNewswire Inc.	Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer	NASDAQ:IMMP	Immutep Ltd
10/09/2024	11:54	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMMP	Immutep Ltd
20/08/2024	22:00	GlobeNewswire Inc.	Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024	NASDAQ:IMMP	Immutep Ltd
14/08/2024	22:00	GlobeNewswire Inc.	Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody	NASDAQ:IMMP	Immutep Ltd
07/08/2024	22:00	GlobeNewswire Inc.	Immutep to Participate in Upcoming Investor Conferences	NASDAQ:IMMP	Immutep Ltd
31/07/2024	22:00	GlobeNewswire Inc.	Immutep Quarterly Activities Report Q4 FY24	NASDAQ:IMMP	Immutep Ltd
22/07/2024	22:00	GlobeNewswire Inc.	Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer	NASDAQ:IMMP	Immutep Ltd
17/07/2024	22:00	GlobeNewswire Inc.	Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases	NASDAQ:IMMP	Immutep Ltd
12/07/2024	08:40	GlobeNewswire Inc.	Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	NASDAQ:IMMP	Immutep Ltd
03/07/2024	22:00	GlobeNewswire Inc.	Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results	NASDAQ:IMMP	Immutep Ltd
25/06/2024	22:00	GlobeNewswire Inc.	Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer	NASDAQ:IMMP	Immutep Ltd
05/06/2024	20:00	GlobeNewswire Inc.	Immutep successfully completes institutional placement and institutional component of entitlement offer	NASDAQ:IMMP	Immutep Ltd
04/06/2024	21:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMMP	Immutep Ltd
03/06/2024	10:38	GlobeNewswire Inc.	Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial	NASDAQ:IMMP	Immutep Ltd
15/05/2024	22:00	GlobeNewswire Inc.	Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	NASDAQ:IMMP	Immutep Ltd
02/05/2024	22:00	GlobeNewswire Inc.	Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	NASDAQ:IMMP	Immutep Ltd
29/04/2024	22:00	GlobeNewswire Inc.	Immutep Quarterly Activities Report Q3 FY24	NASDAQ:IMMP	Immutep Ltd
24/04/2024	22:00	GlobeNewswire Inc.	Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	NASDAQ:IMMP	Immutep Ltd
18/04/2024	22:00	GlobeNewswire Inc.	Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	NASDAQ:IMMP	Immutep Ltd
17/04/2024	22:00	GlobeNewswire Inc.	Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	NASDAQ:IMMP	Immutep Ltd
06/03/2024	00:00	GlobeNewswire Inc.	Immutep Announces First Clinical Data from 90mg Dosing of Efti	NASDAQ:IMMP	Immutep Ltd
31/01/2024	08:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMMP	Immutep Ltd
31/01/2024	00:00	GlobeNewswire Inc.	Immutep Quarterly Activities Report Q2 FY24	NASDAQ:IMMP	Immutep Ltd
05/01/2024	00:00	GlobeNewswire Inc.	First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer	NASDAQ:IMMP	Immutep Ltd
22/12/2023	00:00	GlobeNewswire Inc.	Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	NASDAQ:IMMP	Immutep Ltd
21/12/2023	22:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMMP	Immutep Ltd
08/12/2023	00:00	GlobeNewswire Inc.	Immutep Receives A$2.6 million R&D Tax Incentive from French Government	NASDAQ:IMMP	Immutep Ltd